» Articles » PMID: 34440231

How Are Adenosine and Adenosine A Receptors Involved in the Pathophysiology of Amyotrophic Lateral Sclerosis?

Overview
Journal Biomedicines
Date 2021 Aug 27
PMID 34440231
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Adenosine is extensively distributed in the central and peripheral nervous systems, where it plays a key role as a neuromodulator. It has long been implicated in the pathogenesis of progressive neurogenerative disorders such as Parkinson's disease, and there is now growing interest in its role in amyotrophic lateral sclerosis (ALS). The motor neurons affected in ALS are responsive to adenosine receptor function, and there is accumulating evidence for beneficial effects of adenosine A receptor antagonism. In this article, we focus on recent evidence from ALS clinical pathology and animal models that support dynamism of the adenosinergic system (including changes in adenosine levels and receptor changes) in ALS. We review the possible mechanisms of chronic neurodegeneration via the adenosinergic system, potential biomarkers and the acute symptomatic pharmacology, including respiratory motor neuron control, of A receptor antagonism to explore the potential of the A receptor as target for ALS therapy.

Citing Articles

The Impact of Serum Uric Acid on the Progression of Amyotrophic Lateral Sclerosis in Adults Aged 18 and Older: A Systematic Review.

Hussein S, Pingili S, Makkena V, Jaramillo A, Awosusi B, Ayyub J Cureus. 2023; 15(7):e42312.

PMID: 37614251 PMC: 10444204. DOI: 10.7759/cureus.42312.


Molecular and Structural Insight into Adenosine A Receptor in Neurodegenerative Disorders: A Significant Target for Efficient Treatment Approach.

Karati D, Mukherjee S, Roy S Mol Neurobiol. 2023; 60(10):5987-6000.

PMID: 37391647 DOI: 10.1007/s12035-023-03441-5.


The Multifaceted Role of GPCRs in Amyotrophic Lateral Sclerosis: A New Therapeutic Perspective?.

Bassani D, Pavan M, Federico S, Spalluto G, Sturlese M, Moro S Int J Mol Sci. 2022; 23(9).

PMID: 35562894 PMC: 9106011. DOI: 10.3390/ijms23094504.


The Pharmacological Potential of Adenosine A Receptor Antagonists for Treating Parkinson's Disease.

Mori A, Chen J, Uchida S, Durlach C, King S, Jenner P Molecules. 2022; 27(7).

PMID: 35408767 PMC: 9000505. DOI: 10.3390/molecules27072366.

References
1.
Seven Y, Simon A, Sajjadi E, Zwick A, Satriotomo I, Mitchell G . Adenosine 2A receptor inhibition protects phrenic motor neurons from cell death induced by protein synthesis inhibition. Exp Neurol. 2019; 323:113067. PMC: 7336167. DOI: 10.1016/j.expneurol.2019.113067. View

2.
Crotty G, Maciuca R, Macklin E, Wang J, Montalban M, Davis S . Association of caffeine and related analytes with resistance to Parkinson disease among mutation carriers: A metabolomic study. Neurology. 2020; 95(24):e3428-e3437. PMC: 7836665. DOI: 10.1212/WNL.0000000000010863. View

3.
Mayne M, Shepel P, Jiang Y, Geiger J, Power C . Dysregulation of adenosine A1 receptor-mediated cytokine expression in peripheral blood mononuclear cells from multiple sclerosis patients. Ann Neurol. 1999; 45(5):633-9. DOI: 10.1002/1531-8249(199905)45:5<633::aid-ana12>3.0.co;2-x. View

4.
Mori A . How do adenosine A receptors regulate motor function?. Parkinsonism Relat Disord. 2020; 80 Suppl 1:S13-S20. DOI: 10.1016/j.parkreldis.2020.09.025. View

5.
Carruthers A, Sellers L, JENKINS D, Jarvie E, Feniuk W, Humphrey P . Adenosine A(1) receptor-mediated inhibition of protein kinase A-induced calcitonin gene-related peptide release from rat trigeminal neurons. Mol Pharmacol. 2001; 59(6):1533-41. DOI: 10.1124/mol.59.6.1533. View